ENVERIC BIOSCIENCES, INC.

(ENVB)
  Report
Delayed Nasdaq  -  05/18 04:00:00 pm EDT
0.1986 USD   -9.52%
05/18ENVERIC BIOSCIENCES, INC. Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K/A)
AQ
05/17Enveric Biosciences to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022
PR
05/13ENVERIC BIOSCIENCES, INC. Management's discussion and analysis of financial condition and results of operations (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

ENVERIC BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

12/30/2021 | 05:05pm EDT

Item 8.01 Other Events.

During the prior thirty days, Enveric Biosciences, Inc., a Delaware corporation (the "Company" or "ENVB") has issued an aggregate of 1,194,843 shares of common stock in exchange for certain outstanding warrants to purchase an aggregate of 698,517 shares of the Company's common stock at an exercise price of $4.66 pursuant to exchange agreements with the holders of such warrants. The Company believes that these exchanges are beneficial to the Company because the reacquired warrants contained provisions that required the Company to repurchase the warrants for cash at the holder's option and/or "full ratchet" anti-dilution adjustments that may result in a reduction in the exercise price of such warrants and an increase in the number of shares issuable upon exercise thereof under certain circumstances. The Company has cancelled all of the warrants reacquired in such exchanges and they will not be reissued.

The issuance of the shares of the Company's common stock in each exchange agreement was made in reliance on an exemption from registration under Section 3(a)(9) of the Securities Act of 1933, as amended, and in the aggregate constitute less than 5% of the number of shares of the Company's common stock issued and outstanding as of November 9, 2021, as reported on the Company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 15, 2021.

Additionally, as previously reported, on September 16, 2021, ENVB completed the previously announced amalgamation of MagicMed Industries Inc., a corporation existing under the laws of the Province of British Columbia ("MagicMed"), pursuant to an amalgamation agreement dated May 24, 2021 (the "Amalgamation Agreement"), by and among ENVB, 1306432 B.C. Unlimited Liability Company (formerly known as 1306432 B.C. Ltd.), an unlimited liability company existing under the laws of the Province of British Columbia and a wholly-owned subsidiary of ENVB ("HoldCo"), 1306436 B.C. Ltd., a corporation existing under the laws of the Province of British Columbia and a wholly-owned subsidiary of HoldCo ("Purchaser"), and MagicMed. Pursuant to the Amalgamation Agreement, Purchaser and MagicMed were amalgamated pursuant to section 269 of the British Columbia Business Corporations Act, with the amalgamated corporation, Enveric Biosciences Canada Inc., surviving as an indirect wholly-owned subsidiary of ENVB (the "Amalgamation").

This Current Report on Form 8-K is being filed in order to provide as Exhibit 99.1 hereto the audited consolidated financial statements of MagicMed for the year ended June 30, 2021 and for the period from incorporation May 26, 2020 to June 30, 2020, and as Exhibit 99.2 hereto the unaudited pro forma condensed consolidated financial information of ENVB and MagicMed for the six months ended June 30, 2021 and the year ended December 31, 2020. The pro forma condensed consolidated financial information included herein has been presented for informational purposes only and is not necessarily indicative of the combined financial position or results of operations that would have been realized had the Amalgamation occurred as of the dates indicated, nor is it meant to be indicative of any anticipated combined financial position or future results of operations that ENVB may experience after the Amalgamation.

The purpose of this Current Report on Form 8-K is to, among other things, file the pro forma condensed consolidated financial information and the financial statements of MagicMed discussed above, and to allow such financial information to be incorporated by reference into ENVB's registration statements filed with the Securities and Exchange Commission.

Item 9.01 Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired.

The audited consolidated financial statements of MagicMed as of June 30, 2021 and for the period from incorporation May 26, 2020 to June 30, 2020, together with the related notes to the financial statements, are filed as Exhibit 99.1 to this Current Report on Form 8-K and are incorporated herein by reference.

(b) Pro Forma Financial Information.

The unaudited pro forma condensed consolidated financial information of ENVB for the six months ended June 30, 2021 and for the year ended December 31, 2020, together with the related notes to the pro forma financial information, and giving effect to the Amalgamation as if it had been completed on June 30, 2021, are filed as Exhibit 99.2 to this Current Report on Form 8-K and are incorporated herein by reference.




(d) Exhibits.



Exhibit No.                                Description
23.1            Consent of Zeifmans LLP
99.1            Audited consolidated financial statements of MagicMed for the year
              ended June 30, 2021 and for the period from incorporation May 26, 2020
              to June 30, 2020
99.2            Unaudited pro forma condensed consolidated financial information of
              ENVB for the six months ended June 30, 2021 and the year ended
              December 31, 2020
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

© Edgar Online, source Glimpses

All news about ENVERIC BIOSCIENCES, INC.
05/18ENVERIC BIOSCIENCES, INC. Material Modification to Rights of Security Holders, Amendme..
AQ
05/17Enveric Biosciences to Participate in the H.C. Wainwright Global Investment Conference ..
PR
05/13ENVERIC BIOSCIENCES, INC. Management's discussion and analysis of financial condition ..
AQ
05/13Enveric Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
05/11ENVERIC BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Regulation FD Disc..
AQ
05/11Enveric Biosciences Plans to Spin-Off Cannabinoid Development Pipeline Assets
CI
05/11Enveric Biosciences Plans to Spin Off Cannabinoid Pipeline
MT
05/11Enveric Biosciences Announces Plans to Spin-off and Dividend its Cannabinoid Pipeline t..
PR
05/11Enveric Biosciences, Inc. agreed to Spin-Off Acanna Therapeutics, Inc.
CI
05/05ENVERIC BIOSCIENCES TO HOST FIRESIDE : 00 a.m. ET
PR
More news
Analyst Recommendations on ENVERIC BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -16,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,40x
Yield 2022 -
Capitalization 10,4 M 10,4 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 24
Free-Float 85,0%
Chart ENVERIC BIOSCIENCES, INC.
Duration : Period :
Enveric Biosciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ENVERIC BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 0,20 $
Average target price 1,10 $
Spread / Average Target 454%
EPS Revisions
Managers and Directors
Joseph Tucker Chief Executive Officer & Director
Avani V. Kanubaddi President & Chief Operating Officer
Carter J. Ward Chief Financial Officer
David Ian Johnson Executive Chairman
Jillian Hagel Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
ENVERIC BIOSCIENCES, INC.-78.65%10
MODERNA, INC.-45.78%56 593
LONZA GROUP AG-27.42%41 313
IQVIA HOLDINGS INC.-30.08%39 122
SEAGEN INC.-7.50%26 976
ICON PUBLIC LIMITED COMPANY-34.37%17 002